Effectiveness and safety of rituximab in special types of rheumatoid arthritis
International Journal of Rheumatic Diseases · 2023-11 · 26 (11) · 2240-2247
DOI: 10.1111/1756-185x.14920 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 13.09.2023. Verfasst von Satoshi Takanashi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Rheumatoid Vasculitis, Arthritis, Rheumatoid, Lymphoproliferative Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To elucidate the efficacy and safety of rituximab in special types of rheumatoid arthritis.
Methods
We retrospectively reviewed all patients with rheumatoid arthritis with lymphoproliferative disorder or vasculitis treated with rituximab between April 2010 and June 2022 at Keio University Hospital. We assessed the effectiveness of rituximab using the Disease Activity Score for 28 joints‐erythrocyte sedimentation rate (DAS28‐ESR), Clinical Disease Activity Index (CDAI), and safety of rituximab during the disease course. We also assessed the glucocorticoid‐sparing effects of rituximab.
Results
We included eight patients with a history of lymphoproliferative disorder and five patients with rheumatoid vasculitis. They were treated with rituximab without high‐dose glucocorticoid. The mean DAS28‐ESR and CDAI scores significantly improved 12 months after rituximab administration (DAS28‐ESR, 4.7 vs. 2.7, p < .001; CDAI, 16.0 vs. 5.1, p = .006, respectively), and the dose of prednisolone was reduced from a mean of 7.4 mg/day to 4.0 mg/day at 12 months ( p = .05) and 3.2 mg/day at the last visit ( p = .04). During the mean follow‐up period of 52 months, we recorded one recurrence of lymphoproliferative disorder (not B‐cell type) in patients with a history of lymphoproliferative disorder and remarkable improvement of skin ulcers in patients with vasculitis.
Conclusion
B‐cell depletion by rituximab may be a useful treatment option for patients with lymphoproliferative disorder and rheumatoid vasculitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Satoshi Takanashi, Hironari Hanaoka, Tsutomu Takeuchi, Yuko Kaneko
Zitieren
APA
Takanashi, S., Kondo, Y., Saito, S., Kikuchi, J., Hanaoka, H., Takeuchi, T., & Kaneko, Y. (2023). Effectiveness and safety of rituximab in special types of rheumatoid arthritis. International Journal of Rheumatic Diseases, 26(11), 2240-2247. https://doi.org/10.1111/1756-185x.14920
Vancouver
Takanashi S, Kondo Y, Saito S, Kikuchi J, Hanaoka H, Takeuchi T, et al. Effectiveness and safety of rituximab in special types of rheumatoid arthritis. International Journal of Rheumatic Diseases. 2023;26(11):2240-2247. doi:10.1111/1756-185x.14920
BibTeX
@article{Takanashi2023,
author = {Takanashi, Satoshi and Kondo, Yasushi and Saito, Shuntaro and Kikuchi, Jun and Hanaoka, Hironari and Takeuchi, Tsutomu and Kaneko, Yuko},
title = {Effectiveness and safety of rituximab in special types of rheumatoid arthritis},
journal = {International Journal of Rheumatic Diseases},
year = {2023},
volume = {26},
number = {11},
pages = {2240--2247},
doi = {10.1111/1756-185x.14920}
}
EUVIMED